Literature DB >> 34995355

Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML.

Gabrielle Paras1, Linde M Morsink2,3, Megan Othus4, Filippo Milano2,5, Brenda M Sandmaier2,5, Lucas C Zarling1, Raffaele Palmieri2,6, Gary Schoch2, Chris Davis2, Marie Bleakley2,7, Mary E D Flowers2,5, H Joachim Deeg2,5, Frederick R Appelbaum2,5, Rainer Storb2,5, Roland B Walter2,8,9,10.   

Abstract

In acute myeloid leukemia (AML), measurable residual disease (MRD) before or after allogeneic hematopoietic cell transplantation (HCT) is an established independent indicator of poor outcome. To address how peri-HCT MRD dynamics could refine risk assessment across different conditioning intensities, we analyzed 810 adults transplanted in first or second remission after myeloablative conditioning (MAC; n = 515) or non-MAC (n = 295) who underwent multiparameter flow cytometry-based MRD testing before as well as 20 to 40 days after allografting. Patients without pre- and post-HCT MRD (MRDneg/MRDneg) had the lowest risks of relapse and highest relapse-free survival (RFS) and overall survival (OS). Relative to those patients, outcomes for MRDpos/MRDpos and MRDneg/MRDpos patients were poor regardless of conditioning intensity. Outcomes for MRDpos/MRDneg patients were intermediate. Among 161 patients with MRD before HCT, MRD was cleared more commonly with a MAC (85 of 104; 81.7%) than non-MAC (33 of 57; 57.9%) regimen (P = .002). Although non-MAC regimens were less likely to clear MRD, if they did, the impact on outcome was greater. Thus, there was a significant interaction between conditioning intensity and "MRD conversion" for relapse (P = .020), RFS (P = .002), and OS (P = .001). Similar findings were obtained in the subset of 590 patients receiving HLA-matched allografts. C-statistic values were higher (indicating higher predictive accuracy) for peri-HCT MRD dynamics compared with the isolated use of pre-HCT MRD status or post-HCT MRD status for prediction of relapse, RFS, and OS. Across conditioning intensities, peri-HCT MRD dynamics improve risk assessment over isolated pre- or post-HCT MRD assessments in patients with AML.
© 2022 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2022        PMID: 34995355      PMCID: PMC8931514          DOI: 10.1182/blood.2021014804

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

1.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

2.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

Authors:  David Grimwade; Robert K Hills; Anthony V Moorman; Helen Walker; Stephen Chatters; Anthony H Goldstone; Keith Wheatley; Christine J Harrison; Alan K Burnett
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

3.  Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach.

Authors:  Brent L Wood
Journal:  Curr Protoc Cytom       Date:  2020-06

Review 4.  Measurable residual disease testing in acute myeloid leukaemia.

Authors:  C S Hourigan; R P Gale; N J Gormley; G J Ossenkoppele; R B Walter
Journal:  Leukemia       Date:  2017-04-07       Impact factor: 11.528

Review 5.  Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations.

Authors:  Roland B Walter; Yishai Ofran; Agnieszka Wierzbowska; Farhad Ravandi; Christopher S Hourigan; Lok Lam Ngai; Adriano Venditti; Francesco Buccisano; Gert J Ossenkoppele; Gail J Roboz
Journal:  Leukemia       Date:  2021-03-23       Impact factor: 11.528

6.  Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.

Authors:  Dimitri A Breems; Wim L J Van Putten; Georgine E De Greef; Shama L Van Zelderen-Bhola; Klasien B J Gerssen-Schoorl; Clemens H M Mellink; Aggie Nieuwint; Martine Jotterand; Anne Hagemeijer; H Berna Beverloo; Bob Löwenberg
Journal:  J Clin Oncol       Date:  2008-08-11       Impact factor: 44.544

7.  Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease.

Authors:  Linde M Morsink; Evandro D Bezerra; Megan Othus; Brent L Wood; Min Fang; Brenda M Sandmaier; Marco B Mielcarek; H Joachim Deeg; Gary Schoch; Frederick R Appelbaum; Roland B Walter
Journal:  Leukemia       Date:  2019-12-03       Impact factor: 11.528

8.  2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.

Authors:  Michael Heuser; Sylvie D Freeman; Gert J Ossenkoppele; Francesco Buccisano; Christopher S Hourigan; Lok Lam Ngai; Jesse M Tettero; Costa Bachas; Constance Baer; Marie-Christine Béné; Veit Bücklein; Anna Czyz; Barbara Denys; Richard Dillon; Michaela Feuring-Buske; Monica L Guzman; Torsten Haferlach; Lina Han; Julia K Herzig; Jeffrey L Jorgensen; Wolfgang Kern; Marina Y Konopleva; Francis Lacombe; Marta Libura; Agata Majchrzak; Luca Maurillo; Yishai Ofran; Jan Philippe; Adriana Plesa; Claude Preudhomme; Farhad Ravandi; Christophe Roumier; Marion Subklewe; Felicitas Thol; Arjan A van de Loosdrecht; Bert A van der Reijden; Adriano Venditti; Agnieszka Wierzbowska; Peter J M Valk; Brent L Wood; Roland B Walter; Christian Thiede; Konstanze Döhner; Gail J Roboz; Jacqueline Cloos
Journal:  Blood       Date:  2021-12-30       Impact factor: 22.113

9.  Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation.

Authors:  R B Walter; B Gyurkocza; B E Storer; C D Godwin; J M Pagel; S A Buckley; M L Sorror; B L Wood; R Storb; F R Appelbaum; B M Sandmaier
Journal:  Leukemia       Date:  2014-06-03       Impact factor: 11.528

10.  Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML.

Authors:  Linde M Morsink; Megan Othus; Evandro D Bezerra; Brent L Wood; Min Fang; Brenda M Sandmaier; Marco Mielcarek; Gary Schoch; Rainer Storb; H Joachim Deeg; Frederick R Appelbaum; Roland B Walter
Journal:  Leukemia       Date:  2020-01-23       Impact factor: 11.528

View more
  3 in total

1.  Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT).

Authors:  Enrico Maffini; Myriam Labopin; Dietrich Wilhelm Beelen; Nicolaus Kroeger; Mutlu Arat; Keith M O Wilson; Jacques-Olivier Bay; Arnold Ganser; Hans Martin; Jakob Passweg; Panagiotis D Kottaridis; Ibrahim Yakoub-Agha; Rocio Parody Porras; Eva Maria Wagner; Jordi Esteve; Francesco Lanza; Arnon Nagler; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2022-07-14       Impact factor: 5.174

2.  Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms.

Authors:  Colin D Godwin; Eduardo Rodríguez-Arbolí; Megan Othus; Anna B Halpern; Jacob S Appelbaum; Mary-Elizabeth M Percival; Paul C Hendrie; Vivian G Oehler; Siobán B Keel; Janis L Abkowitz; Jason P Cooper; Ryan D Cassaday; Elihu H Estey; Roland B Walter
Journal:  Cancers (Basel)       Date:  2022-06-14       Impact factor: 6.575

3.  Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.

Authors:  Lucas C Zarling; Megan Othus; Brenda M Sandmaier; Filippo Milano; Gary Schoch; Chris Davis; Marie Bleakley; H Joachim Deeg; Frederick R Appelbaum; Rainer Storb; Roland B Walter
Journal:  Leukemia       Date:  2022-04-19       Impact factor: 12.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.